EDSA
Edesa Biotech, Inc.
$5.80
+2.65%
$51.6M
No data for this timeframe.
Vol
Market Cap$51.6M
Cap SizeMicro Cap
Inst. Holders11 funds
Inst. Value$4.8M
Inst. Activity1 buys / 0 sells
Insider Activity8B / 0S
Insider Net $$230.8K
Reddit Sentiment50° Neutral
SEC Reports7
Press Releases2
Recent Activity
Jun 11, 2026
offering
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
<p align="justify">TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (
Jun 5, 2026
SEC
Edesa Biotech reported exploratory data for paridiprubart in acute kidney injury (AKI) patients at the ERA Congress. In
8-K — Impact 7/10
Jun 5, 2026
Press
Edesa Biotech reported favorable exploratory data for paridiprubart in acute kidney injury (AKI) patients with respirato
Impact 6/10
Jun 1, 2026
Insider
Nijhawan Pardeep was granted 1,671 shares
Chief Executive Officer
May 29, 2026
SEC
Edesa Biotech held its 2026 Annual Meeting on May 27, 2026, with ~55% of shares represented. Shareholders approved all p
8-K — Impact 3/10
May 27, 2026
Insider
Liu Da David was granted 19,000 shares
Director
May 27, 2026
Insider
Chypyha Joan was granted 19,000 shares
Director
May 15, 2026
SEC
CEO Pardeep Nijhawan voluntarily requested to receive 90% of his monthly base salary in fully vested RSUs instead of cas
8-K — Impact 2/10
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$14.00 (Nov 2025)
Current $5.80
Low $9.00
Median $14.00
High $19.00
2 analysts
$9.00
$19.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 3, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 13, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.38 ▲ +30.9% | $-0.38 — $-0.38 | -52% YoY | 1 |
| Next Q | $-0.40 ▲ +29.2% | $-0.40 — $-0.40 | -25% YoY | 1 |
| Current FY | $-1.57 ▼ -6.3% | $-1.57 — $-1.57 | -24% YoY | 1 |
| Next FY | $-1.96 ▼ -12.6% | $-2.79 — $-1.13 | -25% YoY | 2 |
Latest Reports
BULLISH
8-K
7/10
Edesa Biotech reported exploratory data for paridiprubart in acute kidney injury (AKI) patients at the ERA Congress. In
Jun 5, 2026
BULLISH
Press
6/10
Edesa Biotech reported favorable exploratory data for paridiprubart in acute kidney injury (AKI) patients with respirato
Jun 5, 2026
NEUTRAL
8-K
3/10
Edesa Biotech held its 2026 Annual Meeting on May 27, 2026, with ~55% of shares represented. Shareholders approved all p
May 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Rubric Capital Management LP | $3.6M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $449.6K | — |
| VANGUARD FIDUCIARY TRUST CO | $201.1K | — |
| STATE STREET CORP | $198.6K | DOUBLED |
| COMMONWEALTH EQUITY SERVICES, LLC | $183.1K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Nijhawan Pardeep | A | $0.00 |
| May 27, 2026 | Liu Da | A | $0.00 |
| May 27, 2026 | Chypyha Joan | A | $0.00 |
| May 27, 2026 | Sistilli Carlo | A | $0.00 |
| May 27, 2026 | Olson Charles | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
11 institutional holders with $4.8M total value (915,054 shares) as of 2026-Q1. Top holders: Rubric, VANGUARD, VANGUARD. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Rubric Capital Management LP | 687,500 | $3.6M | 75.1% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 85,966 | $449.6K | 9.4% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 38,446 | $201.1K | 4.2% | — |
| 4 | STATE STREET CORP | 37,979 | $198.6K | 4.2% | DOUBLED +103.3% |
| 5 | COMMONWEALTH EQUITY SERVICES, LLC | 35,003 | $183.1K | 3.8% | TRIM -30.0% |
| 6 | BlackRock, Inc. | 27,709 | $144.9K | 3.0% | — |
| 7 | ROYAL BANK OF CANADA | 1,659 | $9.0K | 0.2% | — |
| 8 | CITIGROUP INC | 487 | $2.5K | 0.1% | — |
| 9 | Vanguard Global Advisers, LLC | 162 | $847.00 | 0.0% | — |
| 10 | TD Waterhouse Canada Inc. | 142 | $792.00 | 0.0% | — |
| 11 | DANSKE BANK A/S | 1 | $5.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | DOUBLED | 18,679 | 37,979 | +103.3% | $198.6K | 2026-Q1 |
| VANGUARD GROUP INC | DOUBLED | 15,864 | 45,543 | +187.1% | $111.1K | 2025-Q3 |
| CITADEL ADVISORS LLC | TRIM | 23,514 | 14,032 | -40.3% | $34.2K | 2025-Q3 |
| UBS Group AG | DOUBLED | 4 | 683 | +16975.0% | $1.4K | 2025-Q2 |
| COMMONWEALTH EQUITY SERVICES, LLC | TRIM | 50,003 | 35,003 | -30.0% | $71.00 | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 31 | 4 | -87.1% | $10.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 4 | 31 | +675.0% | $52.00 | 2024-Q4 |
| MORGAN STANLEY | TRIM | 28 | 14 | -50.0% | $24.00 | 2024-Q4 |
9 unique insiders with 50 transactions. Net insider value: $230.8K ($230.8K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 1,671 | — | — |
| May 27, 2026 | Liu Da David | Director | AWARD | 19,000 | — | — |
| May 27, 2026 | Chypyha Joan | Director | AWARD | 19,000 | — | — |
| May 27, 2026 | Sistilli Carlo | Director | AWARD | 19,000 | — | — |
| May 27, 2026 | Olson Charles V | Director | AWARD | 19,000 | — | — |
| May 27, 2026 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 96,913 | — | — |
| May 27, 2026 | Weiler Peter J. | Chief Financial Officer | AWARD | 64,609 | — | — |
| May 27, 2026 | Brooks Michael J | President | AWARD | 64,609 | — | — |
| May 27, 2026 | Marshall Patrick | Director | AWARD | 19,000 | — | — |
| May 27, 2026 | MacDonald Sean Arthur | Director | AWARD | 19,000 | — | — |
| May 1, 2026 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 1,159 | — | — |
| Apr 1, 2026 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 2,578 | — | — |
| Mar 10, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 1,000 | $6.60 | $6.6K |
| Mar 5, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 10,000 | $3.90 | $39.0K |
| Mar 4, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 10,000 | $4.26 | $42.6K |
| Mar 3, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 10,000 | $3.63 | $36.3K |
| Mar 2, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 2,000 | $2.00 | $4.0K |
| Mar 2, 2026 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 10,016 | — | — |
| Feb 27, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 30,000 | $2.22 | $66.7K |
| Feb 26, 2026 | Nijhawan Pardeep | Chief Executive Officer | BUY | 20,571 | $1.58 | $32.5K |
| Feb 26, 2026 | Brooks Michael J | President | BUY | 2,000 | $1.57 | $3.1K |
| Feb 19, 2026 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 82,236 | — | — |
| Feb 2, 2026 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 11,168 | — | — |
| Jan 5, 2026 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 10,444 | — | — |
| Dec 1, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 8,766 | — | — |
| Nov 3, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 6,968 | — | — |
| Oct 2, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 5,908 | — | — |
| Sep 11, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 5,981 | — | — |
| Aug 1, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 6,802 | — | — |
| Jul 2, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 7,186 | — | — |
| Jun 2, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 7,644 | — | — |
| May 29, 2025 | Liu Da David | Director | AWARD | 5,501 | — | — |
| May 29, 2025 | Weiler Peter J. | Chief Financial Officer | AWARD | 65,000 | — | — |
| May 29, 2025 | Chypyha Joan | Director | AWARD | 11,000 | — | — |
| May 29, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 263,200 | — | — |
| May 29, 2025 | Brooks Michael J | President | AWARD | 207,201 | — | — |
| May 29, 2025 | Marshall Patrick | Director | AWARD | 11,000 | — | — |
| May 29, 2025 | Olson Charles V | Director | AWARD | 11,000 | — | — |
| May 29, 2025 | MacDonald Sean Arthur | Director | AWARD | 20,001 | — | — |
| May 29, 2025 | Sistilli Carlo | Director | AWARD | 20,001 | — | — |
| May 2, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 6,392 | — | — |
| Apr 1, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 5,784 | — | — |
| Mar 3, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 6,339 | — | — |
| Feb 12, 2025 | Marshall Patrick | Director | AWARD | 41,666 | $1.92 | $80.0K |
| Feb 12, 2025 | Sistilli Carlo | Director | AWARD | 10,416 | $1.92 | $20.0K |
| Feb 12, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 100 | — | — |
| Feb 3, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 8,264 | — | — |
| Jan 6, 2025 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 8,476 | — | — |
| Dec 2, 2024 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 6,420 | — | — |
| Nov 12, 2024 | Nijhawan Pardeep | Chief Executive Officer | AWARD | 4,630 | — | — |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 4.4/10.
BULLISH
8-K
7/10
Edesa Biotech reported exploratory data for paridiprubart in acute kidney injury (AKI) patients at t
Jun 5, 2026
NEUTRAL
8-K
3/10
Edesa Biotech held its 2026 Annual Meeting on May 27, 2026, with ~55% of shares represented. Shareho
May 29, 2026
NEUTRAL
8-K
2/10
CEO Pardeep Nijhawan voluntarily requested to receive 90% of his monthly base salary in fully vested
May 15, 2026
NEUTRAL
8-K
4/10
Edesa Biotech reported fiscal Q2 2026 results with a net loss of $4.2M ($0.49/share), wider than the
May 14, 2026
NEUTRAL
PRESS-RELEASE
4/10
Edesa Biotech reported Q2 2026 net loss of $4.2M ($0.49/share), wider than the $1.6M loss ($0.30/sha
May 14, 2026
NEUTRAL
DEFA14A
3/10
Edesa Biotech, Inc. is holding its 2026 Annual General and Special Meeting where shareholders will v
Apr 3, 2026
BULLISH
8-K
8/10
Edesa Biotech announced positive Phase 3 data for its investigational anti-TLR4 antibody, paridiprub
Feb 24, 2026
Historical analyst distribution (last covering-analyst action Nov 2025): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$14.00 mean target (Nov 2025)
$9.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $5.80 |
| Target Low | $9.00 |
| Target Mean | $14.00 |
| Target Median | $14.00 |
| Target High | $19.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.38 | $-0.38 | $-0.38 | -52.0% | +30.9% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.40 | $-0.40 | $-0.40 | -25.0% | +29.2% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-09-30 |
$-1.57 | $-1.57 | $-1.57 | -23.6% | -6.3% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-09-30 |
$-1.96 | $-2.79 | $-1.13 | -24.8% | -12.6% | 0↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.380 | |
| 7d ago | $-0.550 | +0.170 |
| 30d ago | $-0.550 | +0.170 |
| 60d ago | $-0.550 | +0.170 |
| 90d ago | $-0.467 | +0.087 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 3, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 11, 2026
offering
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
<p align="justify">TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopha
Jun 5, 2026
fda
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
<p>TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directe
May 19, 2026
fda
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
<p>TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed
May 19, 2026
short_volume
Short Volume: EDSA — 64.7% short (0.4M / 0.5M)
Short: 352,739 | Exempt: 44,438 | TRF Vol: 545,021 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
<p align="left">TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on d
May 12, 2026
earnings_calendar
EDSA Q2 2026 Earnings Scheduled — 2026-05-12
May 5, 2026
short_interest
FTD: EDSA — 90,026 shares ($1.5M) failed to deliver
Settlement: 20260505, Price: $16.11, FTD Value: $1,450,318.86, EDESA BIOTECH INC COM NEW
Apr 29, 2026
short_interest
FTD: EDSA — 129,961 shares ($1.9M) failed to deliver
Settlement: 20260429, Price: $14.26, FTD Value: $1,853,243.86, EDESA BIOTECH INC COM NEW
Apr 28, 2026
short_interest
FTD: EDSA — 87,480 shares ($1.0M) failed to deliver
Settlement: 20260428, Price: $11.17, FTD Value: $977,151.6, EDESA BIOTECH INC COM NEW
Mar 31, 2026
other
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients <pre>Select
Mar 26, 2026
earnings
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
<p>TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing h
Mar 25, 2026
short_interest
FTD: EDSA — 84,309 shares ($0.6M) failed to deliver
Settlement: 20260325, Price: $7.02, FTD Value: $591,849.18, EDESA BIOTECH INC COM NEW
Mar 20, 2026
short_interest
FTD: EDSA — 97,624 shares ($0.7M) failed to deliver
Settlement: 20260320, Price: $7.23, FTD Value: $705,821.52, EDESA BIOTECH INC COM NEW
Mar 19, 2026
short_interest
FTD: EDSA — 119,430 shares ($0.9M) failed to deliver
Settlement: 20260319, Price: $7.69, FTD Value: $918,416.7, EDESA BIOTECH INC COM NEW
Mar 18, 2026
short_interest
FTD: EDSA — 152,923 shares ($1.1M) failed to deliver
Settlement: 20260318, Price: $7.00, FTD Value: $1,070,461, EDESA BIOTECH INC COM NEW